Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - oxaliplatin, quantity: 200 mg - injection, solution - excipient ingredients: lactose monohydrate; water for injections - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for: - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour; - treatment of advanced colorectal cancer

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - oxaliplatin, quantity: 100 mg - injection, solution - excipient ingredients: water for injections; lactose monohydrate - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for: - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour; - treatment of advanced colorectal cancer

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - oxaliplatin, quantity: 50 mg - injection, solution - excipient ingredients: lactose monohydrate; water for injections - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for: - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour; - treatment of advanced colorectal cancer

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

octapharma ltd - albumin solution human - solution for infusion - 200mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

biotest (uk - albumin solution human - solution for infusion - 200mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

biotest (uk - albumin solution human - solution for infusion - 200mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

csl behring uk ltd - albumin solution human - solution for infusion - 200mg/1ml

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - potassium chloride, quantity: 400 mg/l; sodium lactate, quantity: 3.22 g/l; calcium chloride dihydrate, quantity: 270 mg/l; sodium chloride, quantity: 6 g/l - injection, solution - excipient ingredients: sodium hydroxide; lactic acid; water for injections - is indicated as a source of water and electrolytes. it is also used in patients as a source of bicarbonate in the treatment of mild to moderate metabolic acidosis associated with dehydration or associated with potassium deficiency. these solutions are indicated as methods of intravenous drug delivery, if the drugs are comparable with the solutions. this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - calcium chloride dihydrate, quantity: 270 mg/l; sodium lactate, quantity: 3.22 g/l; potassium chloride, quantity: 400 mg/l; sodium chloride, quantity: 6 g/l - injection, solution - excipient ingredients: sodium hydroxide; water for injections - is indicated as a source of water and electrolytes. it is also used in patients as a source of bicarbonate in the treatment of mild to moderate metabolic acidosis associated with dehydration or associated with potassium deficiency. these solutions are indicated as methods of intravenous drug delivery, if the drugs are comparable with the solutions.

Malta - English - Medicines Authority

baxter holding b.v. kobaltweg 49, 3542ce utrecht, netherlands - calcium chloride, dihydrate, potassium chloride, sodium chloride - solution for infusion - sodium chloride 8.6 g/l potassium chloride 0.3 g/l calcium chloride dihydrate 0.33 g/l - blood substitutes and perfusion solutions